AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AgomAb Therapeutics NV
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026
$8.23−0.05 (-0.60%)
Close on Oct 19, 2026
AgomAb Therapeutics statistics
Financials through Dec 31, 2025, price-based ratios appear once a share price is available, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Market Cap | €183.82K | €878.09M |
| Enterprise Value | -€86.23M | €706.41M |
| PB Ratio | 0.00 | 0.94 |
| P/TBV Ratio | 0.00 | 1.22 |
Income (trailing twelve months)
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Operating Income | -€59.28M | -€54.01M |
| Pretax Income | -€62.55M | -€47.40M |
| Net Income | -€62.55M | €157.18M |
| EBITDA | -€59.06M | -€42.85M |
| EPS (Diluted) | -143.22 EUR | -0.55 EUR |
Returns
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -39.2% | -15.4% |
| Return on Assets (ROA) | -34.7% | -1.57% |
| Return on Invested Capital (ROIC) | -153.3% | 6.28% |
| Return on Capital Employed (ROCE) | -43.9% | -23.8% |
Balance sheet
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | €86.42M | €199.29M |
| Net Cash (Debt) | €86.42M | €111.50M |
| Net Cash Per Share | 3456.72 EUR | 1.53 EUR |
| Equity (Book Value) | €130.90M | €472.30M |
| Book Value Per Share | 5236.08 EUR | 6.00 EUR |
| Tangible Book Value | €102.18M | €50.66M |
| Working Capital | €102.65M | €119.55M |
Financial position
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 6.52 | 3.49 |
| Quick Ratio | 4.65 | 1.51 |
| Interest Coverage | -445.68 | -0.71 |
Cash flow (trailing twelve months)
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -€51.74M | -€42.16M |
Efficiency
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -€1.01M | -€43.26K |
| Employee Count | 62 | 304 |
Dividends and yields
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -34026.2% | 1.60% |
Shares
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 25,000 | 99,540,150 |
| Shares Change (YoY) | 0.00% | 5.61% |
Scores
| Measure | AgomAb Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -0.47 | 1.13 |
| Piotroski F-Score | 3 | 5 |
Calculated by StockData from AgomAb Therapeutics's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.